Erik H van Beers
Overview
Explore the profile of Erik H van Beers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Vliet M, Burgmer P, de Quartel L, Brand J, de Best L, Vietor H, et al.
Genet Test Mol Biomarkers
. 2013 Mar;
17(5):395-400.
PMID: 23485358
Double (bi-allelic) mutations in the gene encoding the CCAAT/enhancer-binding protein-alpha (CEBPA) transcription factor have a favorable prognostic impact in acute myeloid leukemia (AML). Double mutations in CEBPA can be detected...
12.
Joosse S, van Beers E, Tielen I, Horlings H, Peterse J, Hoogerbrugge N, et al.
Breast Cancer Res Treat
. 2008 Aug;
116(3):479-89.
PMID: 18704682
Background: While new defects in BRCA1 are still being found, it is unclear whether current breast cancer diagnostics misses many BRCA1-associated cases. A reliable test that is able to indicate...
13.
Oldenburg R, Kroeze-Jansema K, Houwing-Duistermaat J, Bayley J, Dambrot C, van Asperen C, et al.
Genes Chromosomes Cancer
. 2008 Jul;
47(11):947-56.
PMID: 18663745
Breast cancer accounts for over 20% of all female cancers. A positive family history remains one of the most important risk factors for the disease, with first-degree relatives of patients...
14.
Tischkowitz M, Hamel N, Carvalho M, Birrane G, Soni A, van Beers E, et al.
Eur J Hum Genet
. 2008 Feb;
16(7):820-32.
PMID: 18285836
A number of germ-line mutations in the BRCA1 gene confer susceptibility to breast and ovarian cancer. However, it remains difficult to determine whether many single amino-acid (missense) changes in the...
15.
Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho J, Hamel N, Li G, et al.
Proc Natl Acad Sci U S A
. 2007 Apr;
104(16):6788-93.
PMID: 17420451
No more than approximately 30% of hereditary breast cancer has been accounted for by mutations in known genes. Most of these genes, such as BRCA1, BRCA2, TP53, CHEK2, ATM, and...
16.
Joosse S, van Beers E, Nederlof P
BMC Cancer
. 2007 Mar;
7:43.
PMID: 17343727
Background: Array Comparative Genomic Hybridization (aCGH) is a rapidly evolving technology that still lacks complete standardization. Yet, it is of great importance to obtain robust and reproducible data to enable...
17.
van Beers E, Nederlof P
Breast Cancer Res
. 2006 Jul;
8(3):210.
PMID: 16817944
The introduction of comparative genomic hybridization (CGH) in 1992 opened new avenues in genomic investigation; in particular, it advanced analysis of solid tumours, including breast cancer, because it obviated the...
18.
van Beers E, van Welsem T, Wessels L, Li Y, Oldenburg R, Devilee P, et al.
Cancer Res
. 2005 Feb;
65(3):822-7.
PMID: 15705879
BRCA1 or BRCA2 germline mutations cause approximately 30% of breast cancers within high-risk families. This represents 5% of total breast cancer incidence. Although BRCA1 and BRCA2 are both implicated in...